Itau Unibanco Holding S.A.’s BioCryst Pharmaceuticals BCRX Stock Holding History

Itau Unibanco Holding S.A.’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-377	Closed	-$2.67K	–	383
2023 Q3	$2.67K	Hold	377	–	–	﹤0.01%	462
2023 Q2	$2.65K	Sell	377 -51	-12%	-$409	﹤0.01%	500
2023 Q1	$3.57K	Hold	428	–	–	﹤0.01%	488
2022 Q4	$4.91K	Sell	428 -34	-7%	-$424	﹤0.01%	489
2022 Q3	$6K	Hold	462	–	–	﹤0.01%	511
2022 Q2	$5K	Buy	+462	New	+$4.77K	﹤0.01%	441

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Itau Unibanco Holding S.A.'s BCRX Position: Q4 2023 in Review

Itau Unibanco Holding S.A. sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2023, closing a stake of 377 shares — an estimated $2.67K sold.

Itau Unibanco Holding S.A. first reported a position in BCRX in Q2 2022 and held it in 6 quarters. The position peaked at $6K in Q3 2022. 235 funds tracked by Wall St. Rank hold BCRX as of Q4 2023.

Itau Unibanco Holding S.A. reported no remaining BioCryst Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Itau Unibanco Holding S.A. sold 377 BioCryst Pharmaceuticals shares in Q4 2023, an estimated $2.67K.
Itau Unibanco Holding S.A. first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 6 quarters.
Itau Unibanco Holding S.A.'s BioCryst Pharmaceuticals position peaked at $6K in Q3 2022.
235 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2023.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q4 2023, filed 14 Feb 2024.